{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-042449","form_type":"8-K","ticker":null,"cik":"0000793171","company_name":"Vitro Biopharma, Inc.","filed_at":"2023-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.018385+00:00","generated_at":"2026-06-07T22:26:02.930696+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vitro BioPharma raises $2M via convertible note with 20% OID, warrants, and consulting deal","bullets":["Issued $2.5M principal senior secured convertible note for $2M cash (20% OID); 20% annual interest, matures May 16, 2024 (extendable to Aug 16).","Warrants to purchase common stock, exercisable for 5 years; exercise price based on liquidity event or $95M valuation if no event.","Engaged Alchemy Advisory for 6-month consulting; paid $50K cash, $50K upon IPO/direct listing, and 20K shares (or $300K worth if IPO <$15).","Note secured by all company assets; conversion price equals 70% of liquidity event price (60% if extended) or $95M/fully-diluted shares.","Registration rights agreement filed to register resale of conversion and warrant shares within 30 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-042449","json":"https://secwatch.observer/filing/0001493152-23-042449.json","markdown":"https://secwatch.observer/filing/0001493152-23-042449.md","text":"https://secwatch.observer/filing/0001493152-23-042449.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/793171/000149315223042449/0001493152-23-042449-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/793171/000149315223042449/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:26:02.930696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b32f6d46448230f094f38bc96ad99ae2a0427e2","claim":"Vitro Biopharma, Inc. incurred convertible notes of $2,500,000 with an accredited investor at 20% maturing May 16, 2024.","evidence_excerpt":"On November 16, 2023, Vitro BioPharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor, pursuant to which the Company issued and sold to the investor, in a private placement, (i) a senior secured convertible note (the “Note”) in the principal amount of $2,500,000","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/793171/000149315223042449/0001493152-23-042449-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$2,500,000"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Rate","value":"20%"},{"label":"Maturity","value":"May 16, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"566f86285d1070acb8968f42f043e580093c9ea6","claim":"Vitro Biopharma, Inc. entered into Purchase Agreement with an accredited investor (effective 2023-11-16).","evidence_excerpt":"On November 16, 2023, Vitro BioPharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/793171/000149315223042449/0001493152-23-042449-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Effective","value":"2023-11-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}